Key result
Targeted reduction of apolipoprotein C-III using new agents such as ARO-APOC3 and olezarsen represents a promising approach to treat familial chylomicronaemia syndrome.
Why the study?
Do anti-APOC3 agents like ARO-APOC3 improve biochemical disturbances and reduce pancreatitis risk in patients with familial chylomicronaemia syndrome?
Do anti-APOC3 agents like ARO-APOC3 improve biochemical disturbances and reduce pancreatitis risk in patients with familial chylomicronaemia syndrome?
Answers are grounded in this paper and cite their sources.
Targeted reduction of apolipoprotein C-III using anti-APOC3 agents like ARO-APOC3 represents a promising approach for managing severe hypertriglyceridaemia in familial chylomicronaemia syndrome.
Patients with familial chylomicronaemia syndrome (FCS) have severe hypertriglyceridaemia due to genetically absent lipolytic capacity. They have a poor response to conventional therapies. To reduce the risk of potentially fatal pancreatitis, the management of FCS relies principally on a strict low-fat diet, which is difficult to follow and compromises quality of life. Targeted reduction of apolipoprotein C-III using new anti- APOC3 agents, such as the short interfering RNA ARO-APOC3, represents a promising approach to correct the severe biochemical disturbance in FCS.
No takes yet. Share an insight, caveat, or question.
Robert A. Hegele (2022) conducted an editorial in Familial Chylomicronaemia Syndrome. Anti-APOC3 agents (volanesorsen, olezarsen, ARO-APOC3) was evaluated. Targeted reduction of apolipoprotein C-III using new agents such as ARO-APOC3 and olezarsen represents a promising approach to treat familial chylomicronaemia syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: